Published in Nat Rev Urol on May 31, 2017
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol (2008) 4.88
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol (2014) 3.10
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med (1988) 1.98
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res (2010) 1.91
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res (2010) 1.89
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res (2011) 1.64
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer (2015) 1.62
A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int (2001) 1.50
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol (2016) 1.42
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest (2004) 1.33
Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate (2003) 1.32
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res (2013) 1.18
Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci (2006) 1.14
Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13
Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv Cancer Res (2006) 1.08
The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol (2011) 1.05
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Current vaccination strategies for prostate cancer. Eur Urol (2011) 1.01
T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol (2006) 1.00
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med (2016) 0.99
Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate (2007) 0.98
Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res (2015) 0.95
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate (2005) 0.94
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clin Cancer Res (2015) 0.90
Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res (2004) 0.89
Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother (2012) 0.89
Update on prostate cancer vaccines. Cancer J (2011) 0.88
The present status and future prospects of peptide-based cancer vaccines. Int Immunol (2016) 0.85
Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci (2007) 0.85
Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer. Cancer Immunol Immunother (2011) 0.83
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. BMC Cancer (2013) 0.83
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. Cancer Immunol Immunother (2015) 0.82
A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother (2016) 0.82
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol (2015) 0.82
Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J Immunother (2002) 0.80
Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy (2012) 0.79
Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate (2008) 0.78
IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother (2014) 0.78
Cancer immunotherapy using tumor cryoablation. Immunotherapy (2014) 0.77
Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci (2009) 0.77
Neoantigen-based cancer immunotherapy. Ann Transl Med (2016) 0.75